|
gptkbp:instance_of
|
gptkb:monoclonal_antibody
|
|
gptkbp:administered_by
|
subcutaneous injection
|
|
gptkbp:approves
|
gptkb:FDA
|
|
gptkbp:availability
|
prescription only
|
|
gptkbp:bioavailability
|
high
|
|
gptkbp:capacity
|
1 m L
|
|
gptkbp:chemical_formula
|
C6480 H10080 N1716 O2016 S44
|
|
gptkbp:clinical_trial
|
gptkb:AEGIS_Study
Phase 3
HELP Study
KALAHARI Study
HELP2 Study
|
|
gptkbp:clinical_use
|
long-term prophylaxis
|
|
gptkbp:contraindication
|
hypersensitivity to lanadelumab
|
|
gptkbp:developed_by
|
gptkb:Takeda_Pharmaceutical_Company
|
|
gptkbp:dosage_form
|
solution for injection
|
|
gptkbp:drug_interactions
|
none significant known
|
|
gptkbp:duration
|
ongoing therapy
|
|
gptkbp:effective_date
|
gptkb:2018
|
|
gptkbp:financial_stability
|
stable for 24 months
|
|
gptkbp:financial_support
|
available
|
|
gptkbp:formulation
|
sterile solution
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Lanadelumab
|
|
gptkbp:indication
|
gptkb:hereditary_angioedema
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_monitored_by
|
immune response
renal function
liver function
|
|
gptkbp:lifespan
|
approximately 14 days
|
|
gptkbp:manufacturer
|
gptkb:Takeda
|
|
gptkbp:marketed_as
|
gptkb:Canada
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:mechanism_of_action
|
inhibits plasma kallikrein
|
|
gptkbp:patient_population
|
adults and adolescents
|
|
gptkbp:pharmacokinetics
|
linear pharmacokinetics
inhibition of kallikrein activity
|
|
gptkbp:price
|
high
|
|
gptkbp:route_of_administration
|
subcutaneous
|
|
gptkbp:service_frequency
|
every 2 to 4 weeks
|
|
gptkbp:side_effect
|
fatigue
headache
nausea
diarrhea
injection site reactions
serious allergic reactions
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:targets
|
plasma kallikrein
|
|
gptkbp:trade
|
gptkb:Takhzyro
|
|
gptkbp:used_for
|
prevention of hereditary angioedema attacks
|
|
gptkbp:website
|
abdomen or thigh
|
|
gptkbp:weight
|
146 k Da
|
|
gptkbp:bfsParent
|
gptkb:Shire_plc
|
|
gptkbp:bfsLayer
|
5
|